Sandbox/v20: Difference between revisions

Jump to navigation Jump to search
Gerald Chi (talk | contribs)
Ahmed Zaghw (talk | contribs)
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Endocarditis}}




{{Meningitis}}
<div class="mw-collapsible mw-collapsed">
 
<div class="mw-collapsible-content">
 
</div></div>
 
 
 
<div class="mw-collapsible mw-collapsed">


====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin====
====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin====
<div class="mw-collapsible-content">


{|
{|
Line 97: Line 108:
|}
|}


<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.
</div></div>
 
<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;395(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 395 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref>

Latest revision as of 02:01, 16 January 2014

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Sandbox/v20 On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox/v20

CDC onSandbox/v20

Sandbox/v20 in the news

Blogs on Sandbox/v20

to Hospitals Treating Sandbox/v20

Risk calculators and risk factors for Sandbox/v20



Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin

Enterococcus Susceptible to
Penicillin, Gentamicin, and Vancomycin
Preferred Regimen (Adult)
Ampicillin 2 g IV q4h x 4—6 weeks
OR
Penicillin G potassium 3—5 million U/day IV q4h x 4—6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 4—6 weeks
Preferred Regimen (Pediatric)
Ampicillin 2 g IV q4h x 4—6 weeks
OR
Penicillin G potassium 3—5 million U/day IV q4h x 4—6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 4—6 weeks
Alternative Regimen (Adult)
Vancomycin 15 mg/kg IV q12h x 6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 6 weeks
Alternative Regimen (Pediatric)
Vancomycin 15 mg/kg IV q12h x 6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 6 weeks
Adult, Age <50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
to achieve serum trough concentrations of 15–20 μg/mL
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Adult, Age >50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Immunocompromised
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
Recurrent
Preferred Regimen
Vancomycin 30—60 mg/kg/day IV q8–12h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h